Hikma Pharmaceuticals PLC (OTCMKTS:HKMPF – Get Rating) – Stock analysts at Jefferies Financial Group issued their FY2026 earnings per share estimates for Hikma Pharmaceuticals in a research note issued to investors on Friday, May 20th. Jefferies Financial Group analyst J. Vane-Tempest forecasts that the company will post earnings of $2.37 per share for the year.
Other research analysts have also recently issued research reports about the stock. Zacks Investment Research cut shares of Hikma Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, May 4th. JPMorgan Chase & Co. decreased their price objective on shares of Hikma Pharmaceuticals from GBX 3,000 ($37.75) to GBX 2,900 ($36.49) in a report on Wednesday, March 2nd. Finally, Morgan Stanley decreased their price objective on shares of Hikma Pharmaceuticals from GBX 2,300 ($28.94) to GBX 2,100 ($26.43) in a report on Friday, May 6th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $1,677.00.
About Hikma Pharmaceuticals (Get Rating)
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded.
- Get a free copy of the StockNews.com research report on Hikma Pharmaceuticals (HKMPF)
- Zoom Video Communications Is Primed To Launch Higher
- Institutions Buy The Dip In Petco Health and Wellness Company
- Fundamental Strength Makes Williams-Sonoma One for Your Recovery Watchlist
- Veeva Systems: Increasing NDR and Other Wins
- Autozone Edges Past Advanced Auto Parts In Q1 2022
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.